Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 7Recurrence 4Neoplasm Metastasis 4Lymphoma 4Ovarian Neoplasms 3Solid Tumors 2Sarcoma 2Multiple Myeloma 2Glioblastoma 2Breast Neoplasms 2Solid Tumor 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 41fludarabine 31Dexamethasone 27venetoclax 24Cytarabine 22Rituximab 16pembrolizumab 15fludarabine phosphate 14Filgrastim 12Etoposide 12Lenalidomide 11Vincristine 10Gemcitabine 10Azacitidine 10pomalidomide 9Interleukin-2 9Granulocyte Colony-Stimulating Factor 9Doxorubicin 9Calcium Dobesilate 9carfilzomib 8Topotecan 8Nivolumab 8Methotrexate 8Everolimus 8Decitabine 8Bortezomib 8Melphalan 7Cisplatin 7Vorinostat 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Recurrence × ridaforolimus × Clear all
NCT01380184 2019-04-19

MK-8669-059

Merck Sharp & Dohme LLC

Phase 1 Completed
15 enrolled 15 charts

Neoplasms, Recurrence

NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
24 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT01071304 2015-04-10

Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)

Merck Sharp & Dohme LLC

Phase 1 Completed
16 enrolled

Neoplasm Metastasis, Recurrence

NCT00112372 2015-02-12

Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
147 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡